Executive Chairman and Founder Gabriele Cerrone, through Panetta Partners Ltd, purchased 42,357 common shares at $0.99 per share. This transaction increased his total holding to 44,814,587 common shares, representing 34.93% of the company's issued share capital. Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulation therapies.
